| Patient | John Henry Holliday |
|---|---|
| Date of birth | 1851-08-14 |
| Identifiers | MRN HR-NI007-SYN-TD; SSN (made up) 000-07-8153 |
| Document date | 1873-08-18 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End-of-treatment review after six months. [S]
Mr. Holliday returns five days after his last dose. He completed all 182 doses by video-observed therapy: 56 in the intensive phase and 126 in the continuation phase, with the one dose held during the stomach illness in the spring added at the end. The cultures from the third week and from the two-month visit both grew nothing, so the continuation phase stayed at four months. He has had no cough, fever, night sweats, or weight loss for months, and he has gained 7.5 kg. The repeat liver tests planned two weeks after the sick visit, and the monthly tests in the fourth and fifth months, were not drawn; he reported no hepatitis symptoms on any video call. Since the party in the spring he has had a drink or two at most once a week and no heavy drinking. He sees his counselor once a month. [S]
| Element | Detail |
|---|---|
| Treatment | All 182 doses completed by video-observed therapy |
| Cultures | Third-week and two-month cultures negative |
| Weight | 65.5 kg, up 7.5 kg since diagnosis |
| Alcohol | AUDIT-C 3; no heavy drinking since the spring |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Gastrointestinal | Negative | No nausea, abdominal pain, or jaundice |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 1873-02-12 to 1873-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 1873-02-12 to 1873-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1873-08-18 | Body height | 178 | cm | S |
| 1873-08-18 | Body weight | 65.5 | kg | S |
| 1873-08-18 | Body mass index (BMI) [Ratio] | 20.7 | kg/m2 | S |
| 1873-08-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1873-08-18 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1873-08-18 | Heart rate | 72 | /min | S |
| 1873-08-18 | Respiratory rate | 14 | /min | S |
| 1873-08-18 | Body temperature | 36.6 | Cel | S |
| 1873-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1873-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 1873-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 10-40 U/L | Normal | S |
| 1873-08-18 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1873-08-18 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1873-08-18 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 1873-08-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1873-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 65.5 kg, BMI 20.7 |
| Eyes | No icterus |
| Respiratory | Clear, with no crackles |
| Abdomen | Liver not enlarged |
| Neurological | Normal sensation in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
| Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | No symptoms |
| Examination | Weight | At least monthly during treatment | Completed today | 65.5 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None reported at any observed dose |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 30, AST 28 U/L, bilirubin 0.6 mg/dL, all normal at the end of treatment |
| Laboratory | Liver tests after the sick visit and in months four and five | Two weeks after the sick visit, then monthly | Deferred | Not drawn: no visit was scheduled between the sick visit and the end of treatment, and no standing order was placed. He reported no hepatitis symptoms on daily video calls, and the end-of-treatment tests are normal, so no harm is evident. Corrective action: standing monthly liver-test orders at the start of treatment for every patient with a risk factor |
| Laboratory | Hemoglobin | At the end of treatment when low at baseline | Completed today | 14.4 g/dL, up from 12.6 at diagnosis |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Two consecutive negative cultures (third week and two months); no further sputum needed |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; decides the continuation length in cavitary disease | Completed today | No growth; continuation phase kept at four months |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Completed today | Cavity closed; residual right upper lobe scarring |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All 182 doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine stopped with isoniazid |
| Referral | Notification of treatment completion to the health department | At the end of treatment | Completed today | Sent today |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 3 for the past month |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Low-risk limits agreed now that treatment is over |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Monthly |
| Survey | Depression screen (PHQ-9) | At diagnosis and at the end of treatment | Completed today | PHQ-9 3, item 9 scored 0 |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |
| Referral | Infectious diseases review | At two months and at the end of treatment | Completed today | Dr. Navarro reviewed the end-of-treatment results by message; no routine follow-up |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Adult preventive visit in about a month. Same-day visit for symptoms of relapse. Next scheduled visit 1873-09-22: adult preventive visit. [S]